T-bet: Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5709-5722

  Popescu, Iulia ^a   Pipeling, Matthew R ^a   Shah, Pali D ^b   Orens, Jonathan B ^b   McDyer, John F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYTOMEGALOVIRUS ANTIGEN PP65; EOMESODERMIN; GAMMA INTERFERON; GANCICLOVIR; GRANZYME B; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRANSCRIPTION FACTOR T BET; VALGANCICLOVIR; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EOMES PROTEIN, HUMAN; MATRIX PROTEIN; PHOSPHOPROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; LUNG TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; VIRUS LOAD; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; VIROLOGY; YOUNG ADULT;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECURRENCE; T-BOX DOMAIN PROTEINS; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84912544785     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401436     Document Type: Article

References (47)

1. Fishman, J. A. 2007. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357: 2601-2614.
2. Ljungman, P. 2002. β-Herpesvirus challenges in the transplant recipient. J. Infect. Dis. 186(Suppl. 1): S99-S109.
3. Zamora, M. R. 2004. Cytomegalovirus and lung transplantation. Am. J. Transplant. 4: 1219-1226.
4. Balthesen, M., M. Messerle, and M. J. Reddehase. 1993. Lungs are a major organ site of cytomegalovirus latency and recurrence. J. Virol. 67: 5360-5366.
5. Yusen, R. D., J. D. Christie, L. B. Edwards, A. Y. Kucheryavaya, C. Benden, A. I. Dipchand, F. Dobbels, R. Kirk, L. H. Lund, A. O. Rahmel, and J. Stehlik. 2013. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J. Heart Lung Transplant. 32: 965-978.
6. Snyder, L. D., C. A. Finlen-Copeland, W. J. Turbyfill, D. Howell, D. A. Willner, and S. M. Palmer. 2010. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am. J. Respir. Crit. Care Med. 181: 1391-1396.
7. Estenne, M., J. R. Maurer, A. Boehler, J. J. Egan, A. Frost, M. Hertz, G. B. Mallory, G. I. Snell, and S. Yousem. 2002. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant. 21: 297-310.
8. Westall, G. P., A. Michaelides, T. J. Williams, G. I. Snell, and T. C. Kotsimbos. 2003. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 75: 2064-2068.
9. Kerschner, H., P. Jaksch, G. Karigl, T. Popow-Kraupp, W. Klepetko, and E. Puchhammer-Stöckl. 2009. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation 87: 1720-1726.
10. + T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J. Infect. Dis. 204: 1663-1671.
11. Cruz-Guilloty, F., M. E. Pipkin, I. M. Djuretic, D. Levanon, J. Lotem, M. G. Lichtenheld, Y. Groner, and A. Rao. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J. Exp. Med. 206: 51-59.
12. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244.
13. + T cell differentiation. J. Clin. Invest. 120: 4077-4090.
14. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78: 5535-5545.
15. + effector and memory T cell generation. Nat. Immunol. 4: 835-842.
16. Betts, M. R., and R. A. Koup. 2004. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75: 497-512.
17. Sukdolak, C., S. Tischer, D. Dieks, C. Figueiredo, L. Goudeva, H. G. Heuft, M. Verboom, S. Immenschuh, A. Heim, S. Borchers, et al. 2013. CMV-, EBV-and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol. Blood Marrow Transplant. 19: 1480-1492.
18. Peretz, Y., Z. He, Y. Shi, B. Yassine-Diab, J. P. Goulet, R. Bordi, A. Filali-Mouhim, J. B. Loubert, M. El-Far, F. P. Dupuy, et al. 2012. CD160 and PD-1 coexpression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog. 8: e1002840.
19. Smith, C., D. Elhassen, S. Gras, K. K. Wynn, V. Dasari, J. Tellam, S. K. Tey, S. Rehan, Y. C. Liu, J. Rossjohn, et al. 2012. Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. Blood 120: 3237-3245.
20. + T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117: 3799-3808.
21. + effector T cell responses in the lung allograft predominate over the blood during human primary infection. J. Immunol. 181: 546-556.
22. + T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J. Virol. 83: 2728-2742.
23. Paley, M. A., and E. J. Wherry. 2010. TCF-1 flips the switch on Eomes. Immunity 33: 145-147.
24. + T cell responses during chronic infection. Nat. Immunol. 12: 663-671.
25. + T cell exhaustion versus memory. Immunity 37: 1130-1144.
26. + T cells cooperate to contain chronic viral infection. Science 338: 1220-1225.
27. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
28. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37.
29. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3: 1061-1068.
30. + T cell proliferation. Proc. Natl. Acad. Sci. USA 98: 13878-13883.
31. Whittle, H. C., J. Dossetor, A. Oduloju, A. D. Bryceson, and B. M. Greenwood. 1978. Cell-mediated immunity during natural measles infection. J. Clin. Invest. 62: 678-684.
32. Boni, C., A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102: 968-975.
33. Mathew, A., I. Kurane, S. Green, D. W. Vaughn, S. Kalayanarooj, S. Suntayakorn, F. A. Ennis, and A. L. Rothman. 1999. Impaired T cell proliferation in acute dengue infection. J. Immunol. 162: 5609-5615.
34. Carney, W. P., and M. S. Hirsch. 1981. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J. Infect. Dis. 144: 47-54.
35. Jones, T. R., E. J. Wiertz, L. Sun, K. N. Fish, J. A. Nelson, and H. L. Ploegh. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA 93: 11327-11333.
36. Kavanagh, D. G., U. H. Koszinowski, and A. B. Hill. 2001. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J. Immunol. 167: 3894-3902.
37. Yewdell, J.W., and A. B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3: 1019-1025.
38. + T cells are a consequence of antigen load. J. Virol. 81: 2713-2725.
39. Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
40. Leen, A. M., A. Christin, G. D. Myers, H. Liu, C. R. Cruz, P. J. Hanley, A. A. Kennedy-Nasser, K. S. Leung, A. P. Gee, R. A. Krance, et al. 2009. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114: 4283-4292.
41. Leen, A. M., G. D. Myers, U. Sili, M. H. Huls, H. Weiss, K. S. Leung, G. Carrum, R. A. Krance, C. C. Chang, J. J. Molldrem, et al. 2006. Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12: 1160-1166.
42. Feuchtinger, T., K. Opherk, W. A. Bethge, M. S. Topp, F. R. Schuster, E. M. Weissinger, M. Mohty, R. Or, M. Maschan, M. Schumm, et al. 2010. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
43. Bollard, C. M., S. Gottschalk, V. Torrano, O. Diouf, S. Ku, Y. Hazrat, G. Carrum, C. Ramos, L. Fayad, E. J. Shpall, et al. 2014. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32: 798-808.
44. Limaye, A. P., G. Raghu, D. M. Koelle, J. Ferrenberg, M. L. Huang, and M. Boeckh. 2002. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185: 20-27.
45. Eid, A. J., S. K. Arthurs, P. J. Deziel, M. P. Wilhelm, and R. R. Razonable. 2008. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin. Transplant. 22: 162-170.
46. + and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202: 673-685.
47. Khan, N., R. Bruton, G. S. Taylor, M. Cobbold, T. R. Jones, A. B. Rickinson, and P. A. Moss. 2005. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J. Virol. 79: 2869-2879.